-+ 0.00%
-+ 0.00%
-+ 0.00%

Endovia says FDA grants minor-use status for CannEpil canine bone cancer pain treatment

PUBT·10/05/2026 12:45:40
Listen to the news
Endovia says FDA grants minor-use status for CannEpil canine bone cancer pain treatment
  • Endovia Health Sciences, with Lupvindol BioSciences, won FDA CVM minor-use status for CannEpil in canine bone cancer pain.
  • Decision opens the MUMS conditional approval pathway, allowing potential marketing before full effectiveness data if FDA conditions are met.
  • Companies set an FDA pre-submission meeting for Nov. 19, 2026 to align on studies, manufacturing, and filings.
  • U.S. manufacturing work is underway, targeting a potential veterinary launch in 2027 pending regulatory clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endovia Health Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050845PRIMZONEFULLFEED9839528) on October 05, 2026, and is solely responsible for the information contained therein.